| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P17 | country | Hungary | Q28 |
| | United States of America | Q30 |
| | Spain | Q29 |
| | Italy | Q38 |
| | Belgium | Q31 |
| | Austria | Q40 |
| | Poland | Q36 |
| | Netherlands | Q55 |
| | France | Q142 |
| | United Kingdom | Q145 |
| | Brazil | Q155 |
| | Australia | Q408 |
| | Germany | Q183 |
| P582 | end time | 2020-09-29 | |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 100 | |
| P4844 | research intervention | talazoparib | Q25100990 |
| P6153 | research site | University of Cambridge | Q35794 |
| | Yonsei University | Q39988 |
| | Emory University | Q621043 |
| | University of North Carolina at Chapel Hill | Q192334 |
| | University of Washington | Q219563 |
| | Medical University of Vienna, University Library | Q1625100 |
| | University Hospital Muenster | Q1748138 |
| | Hospital Clinic of Barcelona | Q2371388 |
| | hôpital Foch | Q3145155 |
| | Asan Medical Center | Q4803501 |
| | Box Hill Hospital | Q4951532 |
| | Hospital Virgen de la Victoria (Málaga) | Q5902584 |
| | Seoul National University Bundang Hospital | Q7451677 |
| | Swedish Medical Center | Q7654755 |
| | Washington University in St. Louis | Q777403 |
| | Hannover Medical School | Q911561 |
| | Washington University School of Medicine | Q7972509 |
| | Westmead Hospital | Q7989074 |
| | Carolinas Medical Center | Q17514683 |
| | Regional Hospital San Camillo Forlanini | Q24941324 |
| | Peninsula Health | Q30263908 |
| | Carolina Urologic Research Center | Q30269511 |
| | Virginia Oncology Associates | Q30270654 |
| | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | Q30282164 |
| | Swedish Cancer Institute | Q30282233 |
| | Mount Vernon Hospital | Q30292749 |
| P580 | start time | 2017-07-04 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE) | |